• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules

cafead

Administrator
Staff member
  • cafead   Jul 20, 2022 at 10:03: AM
via A Texas federal court has determined that Daiichi Sankyo willfully infringed a Seagen patent in creating its breast cancer drug Enhertu. But it will not enhance a $41.8 million award resulting from a jury trial in April.

article source
 

<